Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $10.2 million.

  • NewAmsterdam Pharma Co N.V's Gains from Investment Securities rose 1357.14% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year change of. This contributed to the annual value of $19.0 million for FY2024, which is 20.56% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Gains from Investment Securities stood at $10.2 million, which was up 264.29% from $2.8 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Gains from Investment Securities' 5-year high stood at $21.9 million during Q1 2025, with a 5-year trough of $700,000 in Q3 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Gains from Investment Securities value was $10.2 million (recorded in 2025), while the average stood at $10.7 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Gains from Investment Securities plummeted by 56.25% in 2024 and then spiked by 1,357.14% in 2025.
  • Over the past 4 years, NewAmsterdam Pharma Co N.V's Gains from Investment Securities (Quarterly) stood at $11.1 million in 2022, then reached $1.6 million in 2023, then tumbled by 56.25% to $18.5 million in 2024, then surged by 1,357.14% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $2.8 million for Q2 2025, and $21.9 million during Q1 2025.